Accelerating the elimination of hepatitis C in Kuwait: An expert opinion

Fuad Hasan 1, Ahmad Alfadhli 2, Abeer Al-Gharabally 3, Mahmoud Alkhaldi 4, Massimo Colombo 5, Jeffrey V Lazarus 6


 

Affiliations

14 August 2020

-

doi: 10.3748/wjg.v26.i30.4415

Abstract

The hepatitis C virus (HCV) is estimated to affect 71 million people worldwide. In 2016, the World Health Organization adopted the first global health sector strategy to eliminate viral hepatitis as a public health threat by 2030. In December 2018, the European Association for the Study of the Liver, International Liver Foundation convened an expert panel to address the elimination of HCV in Kuwait. Several steps have already been taken to eliminate HCV in Kuwait, including free HCV treatment for Kuwait's citizens, high blood safety standards, and the implementation of screening and awareness programs. The expert panel made several recommendations aimed at accelerating the elimination of HCV in Kuwait: The development of a national strategy and action plan to guide all HCV elimination activities; the formation of a coordination mechanism to support collaboration between hepatitis working committees; the prioritization of micro-elimination at primary, secondary or tertiary facilities, in prisons and rehabilitation centers; and ensuring the involvement of multiple stakeholders - including relevant civil society groups - in all activities. Enhanced screening and linkage to care should be prioritized in Kuwait, with the expansion of the prescriber base to primary healthcare providers and nurse practitioners to be considered. Raising awareness and educating people about HCV infection also remain essential to achieve the goal of HCV elimination. Lastly, a national HCV registry should be developed to help monitor the implementation of viral hepatitis plans and progress towards achieving national and international targets.

Keywords: Awareness; Hepatitis C virus; Kuwait; Micro-elimination; Prescribers; Registries.


 

References

  1.  
    1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–1088. - PMC - PubMed
  2.  
    1. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135–184. - PubMed
  3.  
    1. World Health Organization. Hepatitis C. 2019 [Cited 11 October 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
  4.  
    1. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96–102. - PubMed
  5.  
    1. World Health Organization. Global hepatitis report 2017 [Cited 13 Aug 2019]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255017/WHO-HIV-2017.06-....
  6.  
    1. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021 [Cited 11 October 2019]. Available from: https://apps.who.int/iris/handle/10665/246177.
  7.  
    1. EASL-ILF. Hepatitis C elimination in Kuwait: Recommendations [Cited 13 Aug 2019]. Available from: https://easl-ilf.org/wp-content/uploads/2019/04/HCV-ELimination-in-Kuwai....
  8.  
    1. Klein MB. Hepatitis C virus elimination: time for disruptive innovation. J Int AIDS Soc. 2019;22:e25360. - PMC - PubMed
  9.  
    1. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016;46:116–125. - PubMed
  10.  
    1. Saad MF, Alenezi S, Asker H Kuwait Hepatology Club. Expert opinion on the management of hepatitis C infection in Kuwait. Hepat Med. 2018;10:117–132. - PMC - PubMed
  11.  
    1. Pacsa AS, Al-Mufti S, Chugh TD, Said-Adi G. Genotypes of hepatitis C virus in Kuwait. Med Principles Pract. 2001;10:55–57.
  12.  
    1. Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, Butsashvili M, Metreveli D, Sharvadze L, Alkhazashvili M, Shadaker S, Ward JW, Morgan J, Averhoff F. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep. 2017;66:773–776. - PMC - PubMed
  13.  
    1. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76 Suppl 2:22–25. - PMC - PubMed
  14.  
    1. Committee on a National Strategy for the Elimination of Hepatitis B and C Board on Population Health and Public Health Practice; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine, Buckley GJ, Strom BL , editors. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington (DC): National Academies Press (US); 2016.
  15.  
    1. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C, Strom BL, Buckley GJ, editors. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington (DC): National Academies Press (US); 2017.
  16.  
    1. Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018;25 Suppl 1:6–17. - PubMed
  17.  
    1. Nazareth S, Piercey C, Tibbet P, Cheng W. Innovative practice in the management of chronic Hepatitis C: introducing the nurse practitioner model. Aust J Adv Nurs. 2008;25:107.
  18.  
    1. New York State Department of Health. New York State Hepatitis C Elimination Task Force 2018 [Cited 11 October 2019]. Available From: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/el....
  19.  
    1. Derbala M, Abd Farag E, Al-Romaihi H, Al Kaabi S, Al-Thani M, El Sayed E, Amer A, Himatt S. An overview of the Hepatitis C control plan in Qatar. East Mediterr Health J. 2019;25:362–365. - PubMed
  20.  
    1. Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, Dalekos GN. Aiming towards hepatitis C virus elimination in Greece. Ann Gastroenterol. 2019;32:321–329. - PMC - PubMed
  21.  
    1. Cenderello G, Taramasso L, Marra D, Orcamo P, Pasa A, Di Biagio A. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. Expert Rev Pharmacoecon Outcomes Res. 2019;19:189–193. - PubMed
  22.  
    1. Kracht PAM, Arends JE, van Erpecum KJ, Urbanus A, Willemse JA, Hoepelman AIM, Croes EA. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy. 2018;3:12. - PMC - PubMed
  23.  
    1. Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S. Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. J Hepatol. 2019;70:1043–1045. - PubMed
  24.  
    1. AIDS Foundation of Chicago. Hepatitis C Elimination Task Force [Cited 13 October 2019]. Available from: https://www.aidschicago.org/page/our-work/prevention/hepatitis-c-elimina....
  25.  
    1. Isenhour C, Hariri S, Vellozzi C. Monitoring the hepatitis C care cascade using administrative claims data. Am J Manag Care. 2018;24:232–238. - PMC - PubMed
  26.  
    1. Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV. The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clin Infect Dis. 2019;69:2218–2227. - PubMed
  27.  
    1. Goldberg D, Hutchinson S, Innes H, Dillon J. Scotland’s Hepatitis C Action Plan: Achievements of the First Decade and Proposals for a Scottish Government Strategy (2019) for the Elimination of both Infection and Disease [Cited 6 December 2019] Available from: http://www.natap.org/2019/HCV/1_HCV-Elimination-Scotland-2019-07-31.pdf.
  28.  
    1. US Department of Health and Human Services. Mapping Hepatitis Elimination in Action [Cited 17 August 2019]. Available from: https://www.hhs.gov/hepatitis/get-involved/hepatitis-elimination/index.html.
  29.  
    1. US Department of Health and Human Services. National viral hepatitis action plan 2017-2020 [Cited 17 August 2019]. Available from: https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20A....
  30.  
    1. Pourmarzi D, Smirnov A, Hepworth J, Rahman T, FitzGerald G, Hall L. Elements of community-based models for treating hepatitis C virus in supporting HCV elimination in Australia: A Delphi study. Int J Health Plann Manage. 2019;34:e1247–e1256. - PubMed
  31.  
    1. Saab S, Challita YP, Najarian LM, Guo R, Saggi SS, Choi G. Hepatitis C Screening: Barriers to Linkage to Care. J Clin Transl Hepatol. 2019;7:226–231. - PMC - PubMed
  32.  
    1. Young KL, Huang W, Horsburgh CR, Linas BP, Assoumou SA. Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. J Viral Hepat. 2016;23:274–281. - PMC - PubMed
  33.  
    1. Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD. Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. Open Forum Infect Dis. 2017;4:ofx109. - PMC - PubMed
  34.  
    1. Falade-Nwulia O, Mehta SH, Lasola J, Latkin C, Niculescu A, O'Connor C, Chaulk P, Ghanem K, Page KR, Sulkowski MS, Thomas DL. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat. 2016;23:366–374. - PMC - PubMed
  35.  
    1. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and Management of Hepatitis C. Am Fam Physician. 2015;91:835–842. - PubMed
  36.  
    1. Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med. 2019;286:503–525. - PubMed
  37.  
    1. Kushner R. Micro-elimination of hepatitis C: A pathway to achieve national elimination goals. 2019 [Cited 7 December 2019]. Available from: https://www.catie.ca/en/pif/spring-2019/micro-elimination-hepatitis-c-pa....
  38.  
    1. Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. - PMC - PubMed
  39.  
    1. Levy MH, Larney S. The ethics of hepatitis C "treatment as prevention" among prisoners. Hepatology. 2015;61:402. - PubMed
  40.  
    1. Martin NK, Vickerman P, Goldberg D, Hickman M. HCV treatment as prevention in prison: key issues. Hepatology. 2015;61:402–403. - PubMed
  41.  
    1. Hiebert L, Hecht R, Soe-Lin S, Mohamed R, Shabaruddin FH, Syed Mansor SM, Dahlui M, Azzeri A, McDonald SA. A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs. Value Health Reg Issues. 2019;18:112–120. - PubMed
  42.  
    1. Zuckerman A, Carver A, Chastain CA. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes. Curr Treat Options Infect Dis. 2018;10:431–446. - PMC - PubMed
  43.  
    1. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2016;62:298–304. - PMC - PubMed
  44.  
    1. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319–1329. - PMC - PubMed
  45.  
    1. Lazarus JV, Wiktor S, Colombo M, Thursz M EASL International Liver Foundation. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017;67:665–666. - PubMed
  46.  
    1. Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Semin Liver Dis. 2018;38:181–192. - PubMed
  47.  
    1. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J Gastroenterol. 2017;23:151–166. - PMC - PubMed
  48.  
    1. Centers for Disease Control and Prevention (CDC) Hepatitis C [Cited 10 February, 2020]. Available from: https://www.cdc.gov/knowmorehepatitis/media/pdfs/factsheet-boomers.pdf.
  49.  
    1. Crowley D, Murtagh R, Cullen W, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, O'Connor E, O'Reilly D, Betts-Symonds G, Tobin C, Van Hout MC, Lambert JS. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. Harm Reduct J. 2019;16:42. - PMC - PubMed
  50.  
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–e1207. - PMC - PubMed
  51.  
    1. Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, Hernandez UB, Sigmundsdóttir G, Hellard M. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. J Hepatol. 2018;68:932–939. - PubMed
  52.  
    1. Lee SS, Crofts N, Hung CC. Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs. Int J Infect Dis. 2019;85:141–142. - PubMed
  53.  
    1. Butler K, Larney S, Day CA, Burns L. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug Alcohol Rev. 2019;38:264–269. - PubMed
  54.  
    1. The Lancet Hiv. Microelimination could be a big deal for HCV and HIV services. Lancet HIV. 2018;5:e605. - PubMed
  55.  
    1. Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective. Harm Reduct J. 2018;15:62. - PMC - PubMed
  56.  
    1. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S and the ASCEND Providers. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017;167:311–318. - PMC - PubMed
  57.  
    1. Koren DE, Zuckerman A, Teply R, Nabulsi NA, Lee TA, Martin MT. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model. Open Forum Infect Dis. 2019;6 - PMC - PubMed
  58.  
    1. Terrault NA. Hepatitis C elimination: challenges with under-diagnosis and under-treatment. F1000Res. 2019;8:F1000 Faculty Rev–54. - PMC - PubMed
  59.  
    1. Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. J Virus Erad. 2019;5:60–66. - PMC - PubMed
  60.  
    1. Ha S, Timmerman K. Awareness and knowledge of hepatitis C among health care providers and the public: A scoping review. Can Commun Dis Rep. 2018;44:157–165. - PMC - PubMed
  61.  
    1. Collier MG, Bhaurla SK, Cuevas-Mota J, Armenta RF, Teshale EH, Garfein RS. Awareness of HCV infection among persons who inject drugs in San Diego, California. Am J Public Health. 2015;105:302–303. - PMC - PubMed
  62.  
    1. Jost JJ, Tempalski B, Vera T, Akiyama MJ, Mangalonzo AP, Litwin AH. Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs. Int J Environ Res Public Health. 2019;16:1958. - PMC - PubMed
  63.  
    1. US Department of Health and Human Services. Action Plan for the Prevention, Care, Treatment of Viral Hepatitis [Cited 10 October 2019]. Available from: https://www.hhs.gov/sites/default/files/viral-hepatitis-action-plan.pdf.
  64.  
    1. US National Library of Medicine. Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan [Cited 10 February 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT03200379.
  65.  
    1. US National Library of Medicine. HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network [Cited 10 February 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT01474811.
  66.  
    1. Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, Belperio PS, Mole LA. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16:775–783. - PMC - PubMed
  67.  
    1. Rizk C, Miceli J, Shiferaw B, Malinis M, Barakat L, Ogbuagu O, Villanueva M. Implementing a Comprehensive HCV Clinic within an HIV Clinic: A Model of Care for HCV Micro-elimination. Open Forum Infect Dis. 2019:Online ahead of print. - PMC - PubMed
  68.  
    1. Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, Pathil-Warth A, Schlag M, Nalpas C, Wegner S, Lonjon-Domanec I, Simon KG. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015. Z Gastroenterol. 2019;57:584–592. - PubMed
  69.  
    1. Bielen R, Koc ÖM, Busschots D, Robaeys G, Aertgeerts B, Vaes B, Mamouris P, Mathei C, Goderis G, Nevens F. Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. BMJ Open. 2019;9:e026464. - PMC - PubMed
  70.  
    1. Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49:1052–1059. - PubMed

Page Navigation